| Aug 6 |
3 Biotech Stocks to Sell in August Before They Crash & Burn
|
| Jul 31 |
Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024
|
| Jul 30 |
Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study
|
| Jul 23 |
Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors
|
| Jul 18 |
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
| Jul 12 |
The one-year returns have been notable for Ocular Therapeutix (NASDAQ:OCUL) shareholders despite underlying losses increasing
|
| Jul 10 |
Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting
|
| Jul 8 |
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Jun 25 |
Investor Day Slides
|
| Jun 20 |
Ocular Therapeutix jumps as TD Cowen upgrades to Buy and hikes PT
|
